The influence of thrombotic risk factors when oral contraceptives are prescribed. A control-only study

Acta Obstetricia et Gynecologica Scandinavica

Volumn 76, Issue 3, 1997, Pages 252-260

  Lidegaard, Øjvind ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NONE   (Denmark)

Author keywords

Confounder control; Deep venous thrombosis; Epidemiology; Oral contraceptives; Thrombosis; Venous thromboembolism

Indexed keywords

GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ARTICLE; BODY MASS; DEEP VEIN THROMBOSIS; DISEASE PREDISPOSITION; EDUCATION; FEMALE; HUMAN; MIGRAINE; MULTIVARIATE ANALYSIS; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; STROKE; THROMBOSIS;

EID: 0030902131     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0412.1997.tb07855.x     Document Type: Article

References (17)

1. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-82.
2. World Health Organization Collaborative Study on cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-8.
3. Bloemenkamp KWM, Rosendaal FR, Heimerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-6.
4. Jick H, Jick SS, Gurewich Y Myers MW, Vasilakis C. Risk of ideopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
5. Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. BMJ 1996; 312: 83-7.
6. Lewis MA, Spitzer WO, Heinemann LAJ, MacRae KD, Bruppacher R, Thorogood M. Third generations oral contraceptives and risk of myocardial infarction: an international case-control study. BMJ 1996; 312: 88-90.
7. Lewis MA, Heinemann LAJ, MacRae KD, Bruppacher R, Spitzer WO. The increased risk of venous thromboembolism and the use of third generation progestagens: role of bias in observational research. Contraception 1996; 54: 5-13.
8. Lidegaard Ø. Oral contraception in Denmark in 1983. (Da). Ugeskr Laeger 1984; 146: 1172-4.
9. Lidegaard Ø. Use of oral contraceptives in Denmark from 1980-1990 and smoking habits among fertile women in 1990. (da). Ugeskr Laeger 1993; 155: 3550-8.
10. Thorogood M, Vessey MP. Trends in use of oral contraceptives in Britain. Br J Fam Plann 1990; 16: 41-56.
11. Lidegaard Ø, Overgaard K, Hauch O. The oral contraceptive user. Acta Obstet Gynecol Scand 1988; 67: 27-31.
12. Thorogood M, Vessey M. Oral contraceptive prescribing in the presence of risk factors. Br J Fam Plann 1991; 17: 2-3.
13. Sartwell PE, Masi AT, Arthes FG, Greene GR, Smith HE. Thromboembolism and oral contraceptives: An epidemiologic case-control study. Am J Epidemiol 1969; 90: 365-80.
14. Böttiger LE, Boman G, Eklund G, Westerholm B. Oral contraceptives and thromboembolic disease: Effects of lowering oestrogen content. Lancet 1980; i: 1097-1101.
15. Böttiger LE, Westerholm B. Oral contraceptives and thromboembolic disease. Acta Med Scand 1991; 190: 455-63.
16. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Br Med J 1969; 2: 651-7.
17. Lidegaard Ø. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. BMJ 1993; 306: 956-63.